Cargando…
Fecal Biomarkers of Neutrophil and Eosinophil Origin Reflect the Response to Biological Therapy and Corticosteroids in Patients With Inflammatory Bowel Disease
INTRODUCTION: Fecal calprotectin (FC) is a noninvasive tool for examining response to biologics in inflammatory bowel disease (IBD), but its performance in relation to other novel fecal markers of various cellular origins is unknown. METHODS: We performed a prospective multicenter cohort study and i...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10462075/ https://www.ncbi.nlm.nih.gov/pubmed/37256716 http://dx.doi.org/10.14309/ctg.0000000000000605 |
_version_ | 1785097985235877888 |
---|---|
author | Ling Lundström, Maria Peterson, Christer Lampinen, Maria Hedin, Charlotte R. H. Keita, Åsa V. Kruse, Robert Magnusson, Maria K. Lindqvist, Carl Mårten Repsilber, Dirk D'Amato, Mauro Hjortswang, Henrik Strid, Hans Rönnblom, Anders Söderholm, Johan D. Öhman, Lena Venge, Per Halfvarson, Jonas Carlson, Marie |
author_facet | Ling Lundström, Maria Peterson, Christer Lampinen, Maria Hedin, Charlotte R. H. Keita, Åsa V. Kruse, Robert Magnusson, Maria K. Lindqvist, Carl Mårten Repsilber, Dirk D'Amato, Mauro Hjortswang, Henrik Strid, Hans Rönnblom, Anders Söderholm, Johan D. Öhman, Lena Venge, Per Halfvarson, Jonas Carlson, Marie |
author_sort | Ling Lundström, Maria |
collection | PubMed |
description | INTRODUCTION: Fecal calprotectin (FC) is a noninvasive tool for examining response to biologics in inflammatory bowel disease (IBD), but its performance in relation to other novel fecal markers of various cellular origins is unknown. METHODS: We performed a prospective multicenter cohort study and included patients with active IBD who provided a fecal sample at initiation of biological therapy. Levels of FC, myeloperoxidase (MPO), human neutrophil lipocalin (HNL), and eosinophil-derived neurotoxin (EDN) were analyzed and related to clinical remission status at 3 months. Changes in levels of markers at 3 months were calculated, and the impact of concomitant use of corticosteroids at baseline was estimated. RESULTS: In patients achieving clinical remission (n = 27), a decrease in levels of FC (P = 0.005), MPO (P < 0.001), HNL (P < 0.001), and EDN (P < 0.001) was observed, whereas no significant decrease was seen in patients not achieving remission (n = 39). There was a significant difference in the change in the level of MPO (P = 0.01) and HNL (P = 0.02) between patients achieving clinical remission and those who did not, but changes in FC and EDN could not differentiate between these groups. Patients with concomitant systemic corticosteroids at inclusion had lower levels of HNL (P = 0.01) and EDN (P < 0.001) at baseline, compared with patients without corticosteroids. DISCUSSION: Fecal MPO, HNL, and EDN are all promising biomarkers for assessing the treatment outcome of biologics in patients with IBD. Fecal levels of EDN and HNL are significantly affected by corticosteroids indicating a greater sensitivity to the effects of corticosteroids compared with levels of FC and MPO. |
format | Online Article Text |
id | pubmed-10462075 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Wolters Kluwer |
record_format | MEDLINE/PubMed |
spelling | pubmed-104620752023-08-29 Fecal Biomarkers of Neutrophil and Eosinophil Origin Reflect the Response to Biological Therapy and Corticosteroids in Patients With Inflammatory Bowel Disease Ling Lundström, Maria Peterson, Christer Lampinen, Maria Hedin, Charlotte R. H. Keita, Åsa V. Kruse, Robert Magnusson, Maria K. Lindqvist, Carl Mårten Repsilber, Dirk D'Amato, Mauro Hjortswang, Henrik Strid, Hans Rönnblom, Anders Söderholm, Johan D. Öhman, Lena Venge, Per Halfvarson, Jonas Carlson, Marie Clin Transl Gastroenterol Article INTRODUCTION: Fecal calprotectin (FC) is a noninvasive tool for examining response to biologics in inflammatory bowel disease (IBD), but its performance in relation to other novel fecal markers of various cellular origins is unknown. METHODS: We performed a prospective multicenter cohort study and included patients with active IBD who provided a fecal sample at initiation of biological therapy. Levels of FC, myeloperoxidase (MPO), human neutrophil lipocalin (HNL), and eosinophil-derived neurotoxin (EDN) were analyzed and related to clinical remission status at 3 months. Changes in levels of markers at 3 months were calculated, and the impact of concomitant use of corticosteroids at baseline was estimated. RESULTS: In patients achieving clinical remission (n = 27), a decrease in levels of FC (P = 0.005), MPO (P < 0.001), HNL (P < 0.001), and EDN (P < 0.001) was observed, whereas no significant decrease was seen in patients not achieving remission (n = 39). There was a significant difference in the change in the level of MPO (P = 0.01) and HNL (P = 0.02) between patients achieving clinical remission and those who did not, but changes in FC and EDN could not differentiate between these groups. Patients with concomitant systemic corticosteroids at inclusion had lower levels of HNL (P = 0.01) and EDN (P < 0.001) at baseline, compared with patients without corticosteroids. DISCUSSION: Fecal MPO, HNL, and EDN are all promising biomarkers for assessing the treatment outcome of biologics in patients with IBD. Fecal levels of EDN and HNL are significantly affected by corticosteroids indicating a greater sensitivity to the effects of corticosteroids compared with levels of FC and MPO. Wolters Kluwer 2023-06-01 /pmc/articles/PMC10462075/ /pubmed/37256716 http://dx.doi.org/10.14309/ctg.0000000000000605 Text en © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. |
spellingShingle | Article Ling Lundström, Maria Peterson, Christer Lampinen, Maria Hedin, Charlotte R. H. Keita, Åsa V. Kruse, Robert Magnusson, Maria K. Lindqvist, Carl Mårten Repsilber, Dirk D'Amato, Mauro Hjortswang, Henrik Strid, Hans Rönnblom, Anders Söderholm, Johan D. Öhman, Lena Venge, Per Halfvarson, Jonas Carlson, Marie Fecal Biomarkers of Neutrophil and Eosinophil Origin Reflect the Response to Biological Therapy and Corticosteroids in Patients With Inflammatory Bowel Disease |
title | Fecal Biomarkers of Neutrophil and Eosinophil Origin Reflect the Response to Biological Therapy and Corticosteroids in Patients With Inflammatory Bowel Disease |
title_full | Fecal Biomarkers of Neutrophil and Eosinophil Origin Reflect the Response to Biological Therapy and Corticosteroids in Patients With Inflammatory Bowel Disease |
title_fullStr | Fecal Biomarkers of Neutrophil and Eosinophil Origin Reflect the Response to Biological Therapy and Corticosteroids in Patients With Inflammatory Bowel Disease |
title_full_unstemmed | Fecal Biomarkers of Neutrophil and Eosinophil Origin Reflect the Response to Biological Therapy and Corticosteroids in Patients With Inflammatory Bowel Disease |
title_short | Fecal Biomarkers of Neutrophil and Eosinophil Origin Reflect the Response to Biological Therapy and Corticosteroids in Patients With Inflammatory Bowel Disease |
title_sort | fecal biomarkers of neutrophil and eosinophil origin reflect the response to biological therapy and corticosteroids in patients with inflammatory bowel disease |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10462075/ https://www.ncbi.nlm.nih.gov/pubmed/37256716 http://dx.doi.org/10.14309/ctg.0000000000000605 |
work_keys_str_mv | AT linglundstrommaria fecalbiomarkersofneutrophilandeosinophiloriginreflecttheresponsetobiologicaltherapyandcorticosteroidsinpatientswithinflammatoryboweldisease AT petersonchrister fecalbiomarkersofneutrophilandeosinophiloriginreflecttheresponsetobiologicaltherapyandcorticosteroidsinpatientswithinflammatoryboweldisease AT lampinenmaria fecalbiomarkersofneutrophilandeosinophiloriginreflecttheresponsetobiologicaltherapyandcorticosteroidsinpatientswithinflammatoryboweldisease AT hedincharlotterh fecalbiomarkersofneutrophilandeosinophiloriginreflecttheresponsetobiologicaltherapyandcorticosteroidsinpatientswithinflammatoryboweldisease AT keitaasav fecalbiomarkersofneutrophilandeosinophiloriginreflecttheresponsetobiologicaltherapyandcorticosteroidsinpatientswithinflammatoryboweldisease AT kruserobert fecalbiomarkersofneutrophilandeosinophiloriginreflecttheresponsetobiologicaltherapyandcorticosteroidsinpatientswithinflammatoryboweldisease AT magnussonmariak fecalbiomarkersofneutrophilandeosinophiloriginreflecttheresponsetobiologicaltherapyandcorticosteroidsinpatientswithinflammatoryboweldisease AT lindqvistcarlmarten fecalbiomarkersofneutrophilandeosinophiloriginreflecttheresponsetobiologicaltherapyandcorticosteroidsinpatientswithinflammatoryboweldisease AT repsilberdirk fecalbiomarkersofneutrophilandeosinophiloriginreflecttheresponsetobiologicaltherapyandcorticosteroidsinpatientswithinflammatoryboweldisease AT damatomauro fecalbiomarkersofneutrophilandeosinophiloriginreflecttheresponsetobiologicaltherapyandcorticosteroidsinpatientswithinflammatoryboweldisease AT hjortswanghenrik fecalbiomarkersofneutrophilandeosinophiloriginreflecttheresponsetobiologicaltherapyandcorticosteroidsinpatientswithinflammatoryboweldisease AT stridhans fecalbiomarkersofneutrophilandeosinophiloriginreflecttheresponsetobiologicaltherapyandcorticosteroidsinpatientswithinflammatoryboweldisease AT ronnblomanders fecalbiomarkersofneutrophilandeosinophiloriginreflecttheresponsetobiologicaltherapyandcorticosteroidsinpatientswithinflammatoryboweldisease AT soderholmjohand fecalbiomarkersofneutrophilandeosinophiloriginreflecttheresponsetobiologicaltherapyandcorticosteroidsinpatientswithinflammatoryboweldisease AT ohmanlena fecalbiomarkersofneutrophilandeosinophiloriginreflecttheresponsetobiologicaltherapyandcorticosteroidsinpatientswithinflammatoryboweldisease AT vengeper fecalbiomarkersofneutrophilandeosinophiloriginreflecttheresponsetobiologicaltherapyandcorticosteroidsinpatientswithinflammatoryboweldisease AT halfvarsonjonas fecalbiomarkersofneutrophilandeosinophiloriginreflecttheresponsetobiologicaltherapyandcorticosteroidsinpatientswithinflammatoryboweldisease AT carlsonmarie fecalbiomarkersofneutrophilandeosinophiloriginreflecttheresponsetobiologicaltherapyandcorticosteroidsinpatientswithinflammatoryboweldisease |